Cancer Immunotherapy Market : Market Size, Trends, Key Players and Forecast

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.

These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.

According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.

The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.

Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.

According to research report the Cancer Immunotherapy Market is projected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894Market growth factors such as increasing adoption of target therapy over traditional therapy, emergence of biosimilars, increasing demand for mAbs, high prevalence of cancer.

Cancer immunotherapy drugs are designed to alter or boost the body’s natural immune response to fight cancer this market is research-driven with a high degree of dependence on the discovery of molecules that can generate an immune response against various indications.Based on regions, the global Cancer Immunotherapy market is segmented into North America, APAC, Europe and the Rest of the World (RoW).

North America is expected to account for the largest share of the market during the forecast period.

Growth in this regional segment is driven by factors such as increase in patient pool, and initiative taken by the government for the development of Cancer Immunotherapy.In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region.On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators.

The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR from 2016 to 2021.

The high growth in this segment is primarily attributed to the high success rate of these inhibitors.On the basis of applications, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others.

Reports and Data has recently published a new research report on Global Cancer Immunotherapy Market that covers current development scenario and emerging trends of the market.

The research report provides a comprehensive assessment of the market size, market share, revenue growth, and provides a futuristic perspective about the market trends, growth factors, facts, and industry validated market data.

The report applies advanced statistical tools such as Porter’s Five Forces analysis and SWOT analysis to shed light on the competitive landscape of the global Cancer Immunotherapy market.

The report covers all the critical and essential information relating to the global Cancer Immunotherapy market which helps the readers and clients gain a thorough understanding of the market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1550The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers.

The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors.

It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.Key Companies in the market include:Bristol-Myers Squibb, Novartis International Ag, Celgene Corporation, Amgen Inc., Merck & Co. Inc., Janssen Global Services, LLC, Seattle Genetics Inc, Printegra, Gristone Oncology, Inc, Pfizer Inc.Regional segmentation comprises of a current and forecast estimation of the market in the key geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Cancer Immunotherapy Market Research Report: By Type of Therapy (Monoclonal Antibodies, Adoptive Cell Transfer and others), By Application (Lung Cancer, Childhood Cancer and other), By End User (Hospitals, Clinics & others) - Global Forecast till 2027Overview:The global market for Cancer Immunotherapy Market is following a growth track using which it can reach a valuation of USD 101.6 billion by 2023 with a healthy CAGR of 14.8% during the between 2017 and 2023.

This time-frame has been considered by Market Research Future (MRFR) as the forecast period.

The growth in the cancer immunotherapy market can be attributed to various features like the rise in recording of cancer patients, increasing technological interference, better growth possibilities in developing regions due to their rising investment in the healthcare sector, hike in government initiatives, along with private participation, transforming lifestyle where smoking, drinking, and food habits are showing considerable influence, and others can be taken into consideration for better market analysis.

These segments are also getting bolstered by information regarding various factors, valuations, and volumes.By type, the market for Cancer Immunotherapy can be segmented into bacillus calmette-guérin, adoptive cell transfer, monoclonal antibodies, treatment vaccines, cytokines, and others.

These regions are known for their extensive market impact and it can be attributes to their robust infrastructure, better investment in research and development, high per capita income, Easy integration of technologies, better reimbursement policies, and others.

Initiatives taken by governments and private players can influence the market growth.The Asia Pacific market is witnessing high traction from several emerging economies where the healthcare sector is getting revamped.

Understand the various factors that will impact the market growth during the forecast period.

Also, learn about challenges faced by key players and opportunities they can leverage to grow in this market.